Dyadic International Inc DYAI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if DYAI is a good fit for your portfolio.
News
-
Dyadic Reports 2023 Full Year Results and Recent Company Progress
-
Dyadic Announces Change in Board and Management Leadership Roles
-
Dyadic to Attend Industry Events in April
-
Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications
-
Dyadic to Attend Future Food Tech Event March 21 – 22, 2024 in San Francisco, California
-
Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024
-
CORRECTION – Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
-
Dyadic Announces Closing of Private Placement of $6.0 Million Convertible Notes to Accelerate Near-Term Revenue Growth and Commercialization
Trading Information
- Previous Close Price
- $1.80
- Day Range
- $1.65–1.76
- 52-Week Range
- $1.28–2.40
- Bid/Ask
- $1.20 / $2.68
- Market Cap
- $48.68 Mil
- Volume/Avg
- 16,514 / 23,981
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 16.69
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Dyadic International Inc is a world-wide biotechnology platform company. The company has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins, and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 7
- Website
- https://www.dyadic.com
Comparables
Valuation
|
Metric
|
DYAI
|
PTGX
|
EQRX
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 8.23 | 4.38 | 0.97 |
Price/Sales | 16.69 | 24.19 | — |
Price/Cash Flow | — | — | — |
Price/Earnings
DYAI
PTGX
EQRX
Financial Strength
|
Metric
|
DYAI
|
PTGX
|
EQRX
|
|---|---|---|---|
Quick Ratio | 3.44 | 16.54 | 18.43 |
Current Ratio | 3.58 | 16.71 | 18.78 |
Interest Coverage | — | — | — |
Quick Ratio
DYAI
PTGX
EQRX
Profitability
|
Metric
|
DYAI
|
PTGX
|
EQRX
|
|---|---|---|---|
Return on Assets (Normalized) | −59.29% | −16.60% | −15.72% |
Return on Equity (Normalized) | −73.53% | −18.20% | −16.71% |
Return on Invested Capital (Normalized) | −77.72% | −23.45% | −21.31% |
Return on Assets
DYAI
PTGX
EQRX
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Schhmskvm | Pvn | $553.3 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Xtczmyyk | Mkrkxrk | $101.6 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Blpynys | Nsscw | $98.9 Bil | |
MRNA
| Moderna Inc | Fcyszzcg | Gjj | $39.7 Bil | |
ARGX
| argenx SE ADR | Ymvvnqx | Kjwdt | $21.5 Bil | |
BNTX
| BioNTech SE ADR | Slsmyzvn | Bkghd | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Jvvxmbcg | Gwlbfdt | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Bysnclq | Kjtmjvj | $17.2 Bil | |
RPRX
| Royalty Pharma PLC Class A | Rckbqkhmw | Lczwxck | $12.3 Bil | |
INCY
| Incyte Corp | Yvyfcsfcm | Wjxxq | $11.8 Bil |